Skip to main content
Premium Trial:

Request an Annual Quote

HealthTell Completes $26M Series B Financing Round

NEW YORK (GenomeWeb) – Diagnostics developer HealthTell announced today that it has completed a $26 million Series B financing round led by Third Point Ventures.

The company, which also raised $14 million in a previous Series A round, plans to use the proceeds to commercialize panels for tests for autoimmune diseases, such as lupus.

The firm said its Immunosignature Technology platform is best suited to test for these diseases, which can be difficult to diagnose as they mimic other conditions. Instead of directly targeting the disease, the HealthTell test profiles the patient's immune system using a high-density peptide array that is designed to query the antibodies present in a human blood sample, and looks for patterns that correspond to overall health.

HealthTell also said it has developed a pharmaceutical services business that will create companion diagnostics for new and existing drugs. "Our pharmaceutical customers continue to reinforce the need for new tools to stratify patients for drug development trials and to select patients most likely to respond to specific treatments," said CEO Bill Colston in a statement.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.